• 1
    Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469478.
  • 2
    Redd SC. Asthma in the United States: burden and current theories. Environ Health Perspect 2002;110(Suppl. 4):557560.
  • 3
    European Respiratory Society and the European Lung Foundation. European lung white book. Brussels, Belgium: European Respiratory Society and the European Lung Foundation, 2003.
  • 4
    Seung SJ, Mittmann N. Urgent care cost of uncontrolled asthma in Canada, 2004. Can Respir J 2005;12:435436.
  • 5
    Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002;19:6167.
  • 6
    Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004;23:723729.
  • 7
    Turk F, Kay S, Higgins V. The economic and human impact of poor control in patients with severe persistent allergic asthma: results from a multinational study. Thorax 2005;60(Suppl. II):P21.
  • 8
    Van Ganse E, Laforest L, Pietri G, Boissel JP, Gormand F, Ben-Joseph R, et al. Persistent asthma: disease control, resource utilization and direct costs. Eur Respir J 2002;20:260267.
  • 9
    Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 2006;24:11211131.
  • 10
    Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:1248.
  • 11
    Sculpher M. The use of quality-adjusted life-years in cost-effectiveness studies. Allergy 2006;61:527530.
  • 12
    Briggs AH, Bousquet J, Wallace MV, Busse WW, Clark TJ, Pedersen SE, et al. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy 2006;61:531536.
  • 13
    Dewilde S, Turk F, Tambour M, Sandström T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:17651776.
  • 14
    Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309316.
  • 15
    Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302308.
  • 16
    Farahani P, Levine M, Goeree R. A comparison between integrating clinical practice setting and randomized controlled trial setting into economic evaluation models of therapeutics. J Eval Clin Pract 2006;12:463470.
  • 17
    Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701708.
  • 18
    Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473481.
  • 19
    Lowhagen O, Ekstrom L, Holmberg S, Wennerblom B, Rosenfeldt M. Experience of an emergency mobile asthma treatment programme. Resuscitation 1997;35:243247.
  • 20
    CHKS study. Novartis, data on file.
  • 21
    Statistics Canada. Complete life tables, Ontario, 1995–1997. Available at: (Accessed 5 January 2007).
  • 22
    Tsuchiya A, Brazier J, McColl E, Parkin D. Deriving preference-based single indices from non-preference-based condition-specific instruments: Converting AQLQ into EQ-5D indices. Sheffield, UK: ScHARR, University of Sheffield, 2002.
  • 23
    Price D, Brown RE, Lloyd A. Burden of poorly controlled asthma for patients and society in the UK. Prim Care Respir J 2004;13:113.
  • 24
    Ontario Drug Benefit Formulary/Comparative Drug Index No. 39, 2005. Available at: (Accessed 5 January 2007).
  • 25
    Canadian Institute for Health Information. Available at: (Accessed 5 January 2007).
  • 26
    Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92:3239.
  • 27
    Miller MK, Lee JH, Miller DP, Wenzel SE, for the TENOR Study Group. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med 2007, in press.
  • 28
    Slavin R, Fox H, Surrey K, Reisner C. Factors predictive of future clinically significant exacerbations in severe asthma. J Allergy Clin Immunol 2006;117:S274.
  • 29
    Guite HF, Dundas R, Burney PGJ. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. Thorax 1999;54:301307.
  • 30
    Tough SC, Hessel PA, Ruff M, Green FHY, Mitchell I, Butt JC. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35:657665.
  • 31
    Hartert TV, Speroff T, Togias A, Mitchel EF, Snowden MS, Dittus RS, et al. Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma. Ann Allergy Asthma Immunol 2002;89:467473.
  • 32
    Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, O'Byrne PM. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur Respir J 2004;23:287291.
  • 33
    Partridge MR, Van Der Molen T, Myrseth S-E, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13.
  • 34
    Bateman ED, Boushey HA, Bousquet J, Busse W, Clark TJH, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836844.
  • 35
    Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006;10:iiiiv;xi–xiv;1–183.
  • 36
    Forbes C, Shirran L, Bagnall AM, Duffy S, Ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. Health Technol Assess 2001;5:1110.